Aurinia Pharmaceuticals (AUPH) Assets Average (2021 - 2026)

Aurinia Pharmaceuticals has reported Assets Average for 6 years, with the latest figure at $737.8 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 39.8% year-over-year to $737.8 million; the trailing twelve-month figure through Mar 2026 stood at $737.8 million (up 39.8% YoY), and the FY2025 full-year result was $651.1 million, up 18.52% from the prior year.
• Assets Average for Q1 2026 stood at $737.8 million, up from $639.6 million in the prior quarter.
• The five-year high for Assets Average was $737.8 million in Q1 2026, with the low at $461.3 million in Q1 2023.
• Historically, Assets Average has averaged $536.0 million across 5 years, with a median of $525.1 million in 2022.
• Annual changes were most pronounced in 2023 — Assets Average dropped 12.15% — and 2026, when it surged 39.8%.
• Aurinia Pharmaceuticals' Assets Average stood at $479.6 million in 2022, then grew by 15.01% to $551.5 million in 2023, then slipped by 0.28% to $550.0 million in 2024, then increased by 16.28% to $639.6 million in 2025, then gained by 15.36% to $737.8 million in 2026.
• The last three Assets Average figures came in at $737.8 million (Q1 2026), $639.6 million (Q4 2025), and $515.0 million (Q3 2025), per Business Quant data.